Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 2/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 2/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 2/20 | 1.00 |
| ▸ | DGKA | P23743 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | FAAH | O00519 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
| ▸ | CNR2 | P34972 | 1/20 | 0.68 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | SELP | P16109 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5424593 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL10492134 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL16431952 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8384463 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8384469 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| Diolein SCHEMBL160985 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL2179183 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8384789 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL21436106 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8750559 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11504328-B2 | Method for preparing liposome comprising ultrasound reactive microbubble for drug delivery and liposome using same | BIOINFRA LIFE SCIENCE INC. (KR) | 2022-11-22 | — | — | US | claimed |
| EP-3302436-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | The General Hospital Corporation (US) | 2018-04-11 | — | — | EP | claimed |
| WO-2016191556-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | THE GENERAL HOSPITAL CORPORATION (US) | 2016-12-01 | — | — | WO | claimed |
| WO-2024035783-A2 | SULFUR-CONTAINING COMPOUNDS AND COMPOSITIONS THEREOF FOR DELIVERY OF NUCLEIC ACIDS | POSEIDA THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20230380414-A1 | SYSTEMS, DEVICES AND METHODS FOR DELIVERING AEROSOLIZED FLUOROCARBONS | BOUNDLESS SCIENCE LLC (US) | 2023-11-30 | — | — | US | disclosed |
| US-11596645-B2 | Delivery of RNA to trigger multiple immune pathways | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-03-07 | — | — | US | disclosed |
| US-11504328-B2 | Method for preparing liposome comprising ultrasound reactive microbubble for drug delivery and liposome using same | BIOINFRA LIFE SCIENCE INC. (KR) | 2022-11-22 | — | — | US | disclosed |
| US-20220332766-A1 | PRE-FUSION RSV F ANTIGENS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-10-20 | — | — | US | disclosed |
| WO-2022115471-A1 | VACCINATION BY HETEROLOGOUS BOOST IMMUNIZATION | TIBA BIOTECH LLC (US) | 2022-06-02 | — | — | WO | disclosed |
| US-10864162-B2 | Mass production and size control of nanoparticles through controlled microvortices | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-12-15 | — | — | US | disclosed |
| US-10670578-B2 | Controlling translocation through nanopores with fluid walls | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-06-02 | — | — | US | disclosed |
| US-20150182461-A1 | Mass Production and Size Control of Nanoparticles Through Controlled Microvortices | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2015-07-02 | — | — | US | disclosed |
| US-20140335137-A1 | Topical DNA Repair Composition | PHARMA COSMETICS LABORATORIES LTD. (IL) | 2014-11-13 | — | — | US | disclosed |
| US-20140246317-A1 | NANOPORE-BASED DETERMINATION OF PROTEIN CHARGE, SHAPE, VOLUME, ROTATIONAL DIFFUSION COEFFICIENT, AND DIPOLE MOMENT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2014-09-04 | — | — | US | disclosed |
| US-20140242176-A1 | COMPOSITIONS, METHODS, AND DEVICES FOR THE TREATMENT OF EYE STAIN | ADER ENTERPRISES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130177629-A1 | LIPOSOMAL COMPOSITIONS | NUVO RESEARCH GMBH (DE) | 2013-07-11 | — | — | US | disclosed |
| US-20130048499-A1 | CONTROLLING TRANSLOCATION THROUGH NANOPORES WITH FLUID WALL | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-02-28 | — | — | US | disclosed |
| EP-2410990-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING | Marval Biosciences, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110311616-A1 | TARGETING TUMOR ASSOCIATED MACROPHAGES USING BISPHOSPHONATE-LOADED PARTICLES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-22 | — | — | US | disclosed |
| WO-2010107990-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING | MARVAL BIOSCIENCES, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335137-A1 | Topical DNA Repair Composition | ERCC1, UNG, ERCC5 | PRKCA 1701/4885PRKCE 2024/4885PRKCQ 1243/4885 |
| US-20230380414-A1 | SYSTEMS, DEVICES AND METHODS FOR DELIVERING AEROSOLIZED FLUOROCARBONS | PFAS, CFD, AFF1 | PRKCA 4572/4885PRKCE 4645/4885PRKCQ 4252/4885 |
| US-20150182461-A1 | Mass Production and Size Control of Nanoparticles Through Controlled Microvortices | PHOSPHO1, VCL, LIPG | PRKCA 1007/4885PRKCE 1061/4885PRKCQ 1340/4885 |
| US-20110311616-A1 | TARGETING TUMOR ASSOCIATED MACROPHAGES USING BISPHOSPHONATE-LOADED PARTICLES | BPGM, CD209, CD47 | PRKCA 2316/4885PRKCE 2655/4885PRKCQ 2576/4885 |
| US-20220332766-A1 | PRE-FUSION RSV F ANTIGENS | FURIN, CD69, LY96 | PRKCA 4081/4885PRKCE 4299/4885PRKCQ 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.